Ipriflavone
 | |
| Clinical data | |
|---|---|
| Trade names | Yambolap |
| Other names | FLI13; 7-Isopropoxyisoflavone[1] |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.125.854 |
| Chemical and physical data | |
| Formula | C18H16O3 |
| Molar mass | 280.323g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?)(verify) | |
Ipriflavone(INN,JAN;brand nameYambolap) is asyntheticisoflavonewhich may be used to inhibit bone resorption,[2]maintain bone density and to preventosteoporosisin postmenopausal women.[1]It is not used to treat osteoporosis. It slows down the action of theosteoclasts(bone-eroding cells), possibly allowing theosteoblasts(bone-building cells) to build up bone mass.
A clinical trial reported in 2001 that it wasnoteffective in prevention or treatment of osteoporosis.[3]
A double-blind study reveals that ipriflavone might be effective on reducing tinnitus onotosclerosissufferers.[4]
Ipriflavone has been described as aphytoestrogen.[5]However, this is incorrect, as the drug does not bind to or activate theestrogen receptorand shows noestrogeniceffects inpostmenopausalwomen.[6][7]The drug preventsbone lossvia mechanisms that are distinct from those ofestrogens.[5]
References
[edit]- ^abElks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies.Springer. pp. 651–.ISBN978-1-4757-2085-3.
- ^Civitelli R (1997). "In vitro and in vivo effects of ipriflavone on bone formation and bone biomechanics".Calcified Tissue International.61 Suppl 1: S12-4.doi:10.1007/s002239900378.PMID9263610.S2CID21565791.
- ^Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, et al. (Ipriflavone Multicenter European Fracture Study) (March 2001). "Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial".JAMA.285(11): 1482–8.doi:10.1001/jama.285.11.1482.PMID11255425.
- ^Sziklai I, Komora V, Ribári O (1992). "Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis".Acta Chirurgica Hungarica.33(1–2): 101–7.PMID1343452.
- ^abArjmandi BH, Birnbaum RS, Juma S, Barengolts E, Kukreja SC (January 2000). "The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms".Calcified Tissue International.66(1): 61–5.doi:10.1007/s002230050012.PMID10602847.S2CID31022310.
- ^Petilli M, Fiorelli G, Benvenuti S, Frediani U, Gori F, Brandi ML (February 1995). "Interactions between ipriflavone and the estrogen receptor".Calcified Tissue International.56(2): 160–5.doi:10.1007/BF00296349.PMID7736326.S2CID24212438.
- ^Melis GB, Paoletti AM, Cagnacci A, Bufalino L, Spinetti A, Gambacciani M, Fioretti P (November 1992). "Lack of any estrogenic effect of ipriflavone in postmenopausal women".Journal of Endocrinological Investigation.15(10): 755–61.doi:10.1007/BF03347647.PMID1491124.S2CID32186052.
External links
[edit]- Ipriflavoneat PDR Health